A2 Biotherapeutics, a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, announced that it has entered into an agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) in which A2 will continue research and preclinical development of its undisclosed Tmod™ cell therapy candidate, with the parties to co-fund A2’s clinical development and allogeneic manufacturing activities through Phase 1.